Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
天然产物
/
G蛋白偶联受体/G蛋白
结构分类
/
前列腺素受体
其他
/ Tafluprost

他氟前列素 /Tafluprost {[allProObj[0].p_purity_real_show]}

货号：A451878 同义名： AFP-168;MK2452

Tafluprost is an anti-glaucoma prostaglandin (PG) analog.

Tafluprost 化学结构 CAS号：209860-87-7
Tafluprost 化学结构
CAS号：209860-87-7
Tafluprost 3D分子结构
CAS号：209860-87-7
Tafluprost 化学结构 CAS号：209860-87-7
Tafluprost 3D分子结构 CAS号：209860-87-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Tafluprost 纯度/质量文件 产品仅供科研

货号：A451878 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >

Tafluprost 生物活性

描述 Tafluprost is an anti-glaucoma prostaglandin (PG) analog. Tafluprost showed significant IOP(intraocular pressure)-lowering effects without any safety concerns in patients with various types of glaucoma and OH (ocular hypertension) in daily clinical practice and tafluprost is highly effective in any therapeutic patterns[3]. Tafluprost lowers IOP (intraocular pressure) through the prostanoid FP receptor. A part of ocular hypotensive effect of tafluprost is attributed to FP receptor-mediated prostaglandin production acting through the prostanoid EP3 receptor[4]. Tafluprost not only lowers IOP, but may also enhance retinal blood flow in POAG (Primary open-angle glaucoma) patients with a normal IOP[5]. A significant increase of MOPP (mean ocular perfusion pressure) and a decrease of VD (vessel density) in the ONH (inside disc) in patients with initial glaucoma occurred within a week under the topical tafluprost or its FC (fixed combination)[6].

Tafluprost 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01434888 Healthy Volunteers Phase 1 Completed - Finland ... 展开 >> Kuopio University Hospital Eye Clinic Kuopio, Finland, 70200 收起 <<
NCT01654484 Glaucoma and Ocular Hypertensi... 展开 >>on 收起 << Phase 1 Phase 2 Completed - United States, California ... 展开 >> Santen Investigational Site Newport Beach, California, United States, 92663 United States, Florida Santen Investigational Site Deerfield Beach, Florida, United States, 33064 Santen Investigational Site Largo, Florida, United States, 33773 United States, Georgia Santen Investigational Site Morrow, Georgia, United States, 30260 Santen Investigational Site Roswell, Georgia, United States, 30076 United States, New York Santen Investigational Site Rochester, New York, United States, 14618 United States, Ohio Santen Investigational Site Cleveland, Ohio, United States, 44115 United States, Texas Santen Investigational Site Austin, Texas, United States, 78731 Santen Investigational Site Fort Worth, Texas, United States, 76102 Santen Investigational Site San Antonio, Texas, United States, 78240 收起 <<
NCT01927406 Thyroid Eye Disease ... 展开 >> Ocular Hypertension Glaucoma 收起 << Phase 4 Withdrawn(Funding source unava... 展开 >>ilable) 收起 << December 2016 United States, California ... 展开 >> Stanford Hospital and Clinics Stanford, California, United States, 94304 收起 <<

Tafluprost 参考文献

[1]Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014 Apr;31(4):461-71.

[2]Kumagami T, Wakiyama H, et al. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther. 2014 May;30(4):340-5.

[3]Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014 Apr;31(4):461-71

[4]Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol. 2007 May;91(5):673-6

[5]Weindler H, Spitzer MS, Schultheiß M, Kromer R. OCT angiography analysis of retinal vessel density in primary open-angle glaucoma with and without Tafluprost therapy. BMC Ophthalmol. 2020 Nov 12;20(1):444

[6]Kurysheva NI. Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination. Taiwan J Ophthalmol. 2019 Apr-Jun;9(2):93-99

Tafluprost 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.21mL

0.44mL

0.22mL

11.05mL

2.21mL

1.10mL

22.10mL

4.42mL

2.21mL

Tafluprost 技术信息

CAS号209860-87-7
分子式C25H34F2O5
分子量 452.531
别名 AFP-168;MK2452;AFP-168, AFP-168, AFP-168, MK-2452, MK2452, MK 2452, Saflutan, Taflotan, Tapros, Zioptan
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月
溶解度

DMSO: 250 mg/mL(552.45 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

Tags: Tafluprost | 209860-87-7 | AFP-168 | MK2452 | AFP168 | AFP 168 | MK2452 | MK 2452 | MK-2452 | Prostaglandin Receptor Agonist | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Tafluprost 纯度/质量文件 | Tafluprost 生物活性 | Tafluprost 临床数据 | Tafluprost 参考文献 | Tafluprost 实验方案 | Tafluprost 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z